TLDRs; Oracle shares rose modestly as AI cloud expansion confidence continues to support investor sentiment. Stargate project delays caused minor after-hours pullbackTLDRs; Oracle shares rose modestly as AI cloud expansion confidence continues to support investor sentiment. Stargate project delays caused minor after-hours pullback

Oracle (ORCL) Stock; Gains Slightly as AI Cloud Expansion Optimism Persists

2026/02/25 16:12
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDRs;

  • Oracle shares rose modestly as AI cloud expansion confidence continues to support investor sentiment.
  • Stargate project delays caused minor after-hours pullback despite broader market gains.
  • Oracle’s aggressive cloud investments and financing plans remain under investor scrutiny.
  • AI infrastructure demand and Nvidia’s earnings will shape Oracle stock trajectory.

Oracle Corp shares climbed 3.4% during Tuesday’s session, closing at $146.14, before slipping roughly 0.8% in after-hours trading. The movement reflects a broader rebound in U.S. equities, particularly in the technology sector, as investors returned to AI-driven plays after a volatile start to the week.


ORCL Stock Card
Oracle Corporation, ORCL

Analysts note that Oracle’s stock continues to act as a barometer for the market’s appetite for high-cost AI infrastructure investments.

Stargate Delays Temper Optimism

Despite the intraday gains, attention remained focused on OpenAI’s Stargate data-center project. Reports indicate that disagreements over ownership and operational control, rather than chip shortages, have caused delays, raising questions about project timelines.

While the project’s pauses have prompted some caution among traders, many view these hiccups as temporary setbacks rather than structural issues. The after-hours dip signals that investors remain sensitive to any news hinting at slower-than-expected AI expansion.

Oracle’s Ambitious Cloud Plans

Oracle continues to invest heavily in its cloud infrastructure, seeking to secure extended contracts with major AI clients. The company recently outlined a financing strategy targeting $45 billion to $50 billion in 2026 through a combination of debt and equity offerings. In early February, Oracle completed a sizable debt issuance, tapping multiple tranches of senior notes and supplementing them with equity-linked deals, including preferred securities convertible into common stock.

These moves are intended to support the company’s growing cloud ambitions, though some investors remain cautious about the pace of spending relative to returns.

Market Eyes AI Infrastructure Trends

Investor focus is also shifting toward broader AI infrastructure trends, with attention on upcoming earnings reports from key tech players. Nvidia’s post-market results Wednesday are expected to provide fresh insights into AI computing demand, which could influence Oracle’s near-term stock performance. Competition remains fierce, with Amazon’s AWS, Microsoft Azure, and Google Cloud all vying for AI workloads. Analysts say the market is now prioritizing discussions around power, real estate, chips, and financing over feature-level differences between cloud providers.

Oracle’s recovery following a sharp drop on Monday highlights the stock’s resilience, but the company faces ongoing scrutiny regarding both its Stargate involvement and aggressive financing strategy. As the AI landscape evolves, investors will continue weighing the potential upside from cloud expansion against the risks of delays and rising costs.

Investor Caution Meets Growth Potential

As Oracle navigates ambitious cloud expansion and Stargate uncertainties, investors are balancing optimism for AI-driven growth against execution and financing risks. The stock’s modest gains reflect cautious confidence, with traders watching closely for signs of infrastructure scaling and cost management.

The post Oracle (ORCL) Stock; Gains Slightly as AI Cloud Expansion Optimism Persists appeared first on CoinCentral.

Market Opportunity
Cloud Logo
Cloud Price(CLOUD)
$0,03726
$0,03726$0,03726
+0,62%
USD
Cloud (CLOUD) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09